Neuroprotection in acute ischemic stroke. practicability of guidelines for treatment;Neuroprotección en el ictus isquémico agudo. Factibilidad de un protocolo terapéutico

Revista de Neurologia

Volumn 32, Issue 9, 2001, Pages 818-821

  Fridman, E A ^a  

^a Instituto de Investigaciones Neurologicas Raul Carrera   (Argentina)

Author keywords

Cerebral infarction; Citicoline; Clinical trials; Neuroprotectants

Indexed keywords

CITICOLINE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; FEASIBILITY STUDY; FEMALE; HOSPITALIZATION; HUMAN; MALE; PRACTICE GUIDELINE; QUESTIONNAIRE;

ACUTE DISEASE; AGED; BRAIN ISCHEMIA; CYTIDINE DIPHOSPHATE CHOLINE; ENGLISH ABSTRACT; FEASIBILITY STUDIES; FEMALE; GUIDELINES; HUMAN; MALE; MIDDLE AGE; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 1842739154     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3209.2000596     Document Type: Article

References (4)

1. Murray CJL, López AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76.
2. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
3. Hacke W, Kaste M, Fieschi C, Von Kummer R, Davalos A, Meier D, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASSII). Lancet 1998; 352: 1245-51.
4. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999; 282: 2019-26.